medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2017, Number 3

<< Back Next >>

Rev Latin Infect Pediatr 2017; 30 (3)

The immune response against dengue virus and vaccination

Cervantes PP, Ramos CJ

Language: Spanish
References: 36
Page: 102-106
PDF size: 183.75 Kb.


ABSTRACT

Dengue fever is the world's most prevalent vector-borne viral disease. At the end of 2015, the Federal Commission for Protection against Health Risks (COFEPRIS) granted registration of the DENGVAXIA® dengue vaccine from the Sanofi-Pasteur Laboratory for application in Mexico. Following this registration, the World Health Organization recommended, with certain restrictions, the application of this vaccine in national vaccination schemes; Mexico's National Vaccination Council (CONAVA) also established recommendations for the implementation of this vaccine in a public vaccination scheme. The manufacturer presented evidence demonstrating that the effectiveness and safety of DENGVAXIA® were adequate. However, several situations have generated controversy over the application of this vaccine as a public policy. This work describes the immunological behavior of the infection by the four serotypes of the dengue virus (DENV), with emphasis on those related to objections made to the performance of DENGVAXIA®.


REFERENCES

  1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution and burden of dengue. Nature. 2013; 496 (7446): 504-507.

  2. Dantés HG, Farfán-Ale JA, Sarti E. Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. PLoS Negl Trop Dis. 2014; 8 (11): e3158.

  3. World Health Organization. Dengue vaccine: WHO position paper, July 2016-recommendations. Vaccine. 2017; 35: 1200-1201.

  4. Publica SMdS. La Sociedad Mexicana de Salud Pública se enorgullece de haber participado en la integración de una nueva política pública: la introducción de la vacuna de dengue en México. 2016.

  5. Godói IP, Lemos LL, de Araújo VE, Bonoto BC, Godman B, Guerra Júnior AA. CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. J Comp Eff Res. 2017; 6: 165-180.

  6. Halstead SB. Licensed dengue vaccine: public health conundrum and scientific challenge. Am J Trop Med Hyg. 2016; 95: 741-745.

  7. Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res. 2003; 59: 23-61.

  8. Malavige GN, Ogg GS. T cell responses in dengue viral infections. J Clin Virol. 2013; 58: 605-611.

  9. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol. 2005; 3: 13-22.

  10. Amorim JH, Alves RP, Boscardin SB, Ferreira LC. The dengue virus non-structural 1 protein: risks and benefits. Virus Res. 2014; 181: 53-60.

  11. Rodenhuis-Zybert IA, Wilschut J, Smit JM. Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci. 2010; 67 (16): 2773-2786.

  12. Guzman MG, Harris E. Dengue. Lancet. 2015; 385: 453-465.

  13. Comber JD, Karabudak A, Huang X, Piazza PA, Marques ET, Philip R. Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals. Hum Vaccin Immunother. 2014; 10: 3531-3543.

  14. Flipse J, Smit JM. The complexity of a dengue vaccine: a review of the human antibody response. PLoS Negl Trop Dis. 2015; 9: e0003749.

  15. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015; 373: 1195-1206.

  16. Srikiatkhachorn A, Mathew A, Rothman AL. Immune-mediated cytokine storm and its role in severe dengue. Semin Immunopathol. 2017; 39 (5): 563-574.

  17. Yang W, Yan H, Ma Y, Yu T, Guo H, Kuang Y et al. Lower activation-induced T-cell apoptosis is related to the pathological immune response in secondary infection with hetero-serotype dengue virus. Immunobiology. 2016; 221: 432-439.

  18. Harenberg A, de Montfort A, Jantet-Blaudez F, Bonaparte M, Boudet F, Saville M et al. Cytokine profile of children hospitalized with virologically-confirmed dengue during two phase III vaccine efficacy trials. PLoS Negl Trop Dis. 2016; 10: e0004830.

  19. Iani FC, Caldas S, Duarte MM, Cury AL, Cecilio AB, Costa PA et al. Dengue patients with early hemorrhagic manifestations lose coordinate expression of the anti-inflammatory cytokine IL-10 with the inflammatory cytokines IL-6 and IL-8. Am J Trop Med Hyg. 2016; 95: 193-200.

  20. Casals J. Arboviruses. Am J Clin Pathol. 1972; 57: 762-770.

  21. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol. 1989; 70 (Pt 1): 37-43.

  22. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016; 2: 16055.

  23. Snow GE, Haaland B, Ooi EE, Gubler DJ. Review article: Research on dengue during World War II revisited. Am J Trop Med Hyg. 2014; 91: 1203-1217.

  24. Priyamvada L, Cho A, Onlamoon N, Zheng NY, Huang M, Kovalenkov Y et al. B cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Virol. 2016; 90: 5574-5585.

  25. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci USA. 2016; 113: 728-733.

  26. Koraka P, Suharti C, Setiati TE, Mairuhu AT, Van Gorp E, Hack CE et al. Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol. 2001; 39: 4332-4338.

  27. Rothman AL, Medin CL, Friberg H, Currier JR. Immunopathogenesis versus protection in dengue virus infections. Curr Trop Med Rep. 2014; 1: 13-20.

  28. Adams B, Holmes EC, Zhang C, Mammen MP, Jr., Nimmannitya S, Kalayanarooj S et al. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci USA. 2006; 103: 14234-14239.

  29. Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med. 1970; 42: 350-362.

  30. De Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 2014; 10: e1004386.

  31. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004; 189: 990-1000.

  32. Endy TP. Human immune responses to dengue virus infection: lessons learned from prospective cohort studies. Fron Immunol. 2014; 5: 183.

  33. Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014; 209: 360-368.

  34. Moi ML, Takasaki T, Kurane I. Human antibody response to dengue virus: implications for dengue vaccine design. Trop Med Health. 2016; 44: 1.

  35. Forshey BM, Reiner RC, Olkowski S, Morrison AC, Espinoza A, Long KC et al. Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru. PLoS Negl Trop Dis. 2016; 10: e0004398.

  36. Forshey BM, Stoddard ST, Morrison AC. Dengue viruses and lifelong immunity: reevaluating the Conventional Wisdom. J Infect Dis. 2016; 214: 979-981.




2020     |     www.medigraphic.com